Daniel Iniguez

Global Antibiotic R&D Partnership (GARDP)

GARDP is a Swiss not-for-profit organization that develops new treatments for drug-resistant infections that pose the greatest threat to health. GARDP fills critical gaps by driving late-stage antibiotic development and access for people in need all over the world. GARDP's "5 by 25" initiative aims to deliver five new treatments by 2025, including treatments for serious bacterial infections in adults, children and newborns, as well as for sexually transmitted infections. Created in 2016 by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) and legally founded in 2018, GARDP now works with over 70 partners in more than 20 countries with essential funding from governments and private foundations. Together, GARDP and partners are working to preserve the power of antibiotics for now and generations to come.